Skip to content

Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye

Evaluation of Xanthan Gum Eye Drops in Patients With Dry Eye

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01959854
Enrollment
30
Registered
2013-10-10
Start date
2013-09-30
Completion date
2014-10-31
Last updated
2014-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye

Brief summary

The purpose of this study is to evaluate the effect of an ophthalmic solution containing 0.2% xanthan gum in reducing symptoms and signs of dry eye as well as tear film markers of oxidative stress.

Detailed description

Oxidative stress is the result of an imbalance between the production of reactive oxygen species (ROS) and antioxidant systems . The eye is constantly exposed to solar UV radiation which is the major inducer of ROS production and therefore oxidative stress has been implicated in the pathogenesis of several eye disease, including dry eye. Xanthan gum is a complex exopolysaccharide utilized as a food additive. Its chemical structure shows a capacity to react with ROS indicating a role as an anti-oxidative molecule. In the present study aging patients with dry eye will be enrolled. Signs and symptoms of dry eye as well as levels of oxidative stress in tear will be evaluated afte 30 days of treatment with eye drops containing carboxymethylcellulose or xanthan gum.

Interventions

0.25% carboxymethylcellulose preservative free

0.2% xanthan gum preservative free

Sponsors

SIFI SpA
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Ocular Surface Disease Index \> 12\<23 and age \>59 yrs

Exclusion criteria

* contact lens wear and use of other ophthalmic solutions with the exception of artificial tears

Design outcomes

Primary

MeasureTime frameDescription
Ocular surface disease index (OSDI)change from baseline OSDI at 30 daysOSDI is a questionnaire including 12 questions to be asked to the patient. From the questionnaire it will be possible to calculate the OSDI score which is a reliable and valid measurement for dry eye severity.

Secondary

MeasureTime frameDescription
Visual analogue rating scale (VARS)change from baseline VARS at 30 daysGlobal symptoms of dry eye will be graded by patients using a 0-100 mm visual analogue rating scale (0 = no symptoms to 100 = severe symptoms)
Fluorescein stainingchange from baseline staining at 30 daysEye surface damage (corneal and conjunctival) assessed by fluorescein staining will be graded against standard chart (Oxford system)

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026